Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J N Ingle

Showing results (51-60 of 162) with videos related to

Pageof 17
Sort By:
American Journal of Clinical Oncology|December 1, 1995
Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancerJ N Ingle, J E Krook, J A Mailliard, et al.
Cancer Treatment Reports|August 1, 1978
cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lungJ C Britell, R T Eagan, J N Ingle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2009
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009A Goldhirsch, J N Ingle, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2020
Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?A S Coates, A Goldhirsch, R D Gelber, et al.
Cancer Treatment Reports|January 1, 1980
A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancerR T Eagan, T R Fleming, S Frytak, et al.
Cancer Treatment Reports|May 1, 1981
Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancerR T Eagan, S Frytak, W C Nichols, et al.
Oncology|January 1, 1980
An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancerJ Rubin, D A Decker, D L Ahmann, et al.
Cancer Treatment Reports|January 1, 1980
Phase II evaluation of AMSA in patients with metastatic lung cancerW C Nichols, R T Eagan, S Frytak, et al.
Cancer Clinical Trials|January 1, 1981
A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancerR T Eagan, S Frytak, R E Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1980
Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapyR T Eagan, T R Fleming, R E Lee, et al.
Pageof 17

Showing results (51-60 of 162) with videos related to

Sort By:
Pageof 17
American Journal of Clinical Oncology|December 1, 1995
Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancerJ N Ingle, J E Krook, J A Mailliard, et al.
Cancer Treatment Reports|August 1, 1978
cis-Dichlorodiammineplatinum(II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lungJ C Britell, R T Eagan, J N Ingle, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2009
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009A Goldhirsch, J N Ingle, R D Gelber, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2020
Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?A S Coates, A Goldhirsch, R D Gelber, et al.
Cancer Treatment Reports|January 1, 1980
A role of cis-dichlorodiammineplatinum(II) in squamous cell lung cancerR T Eagan, T R Fleming, S Frytak, et al.
Cancer Treatment Reports|May 1, 1981
Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancerR T Eagan, S Frytak, W C Nichols, et al.
Oncology|January 1, 1980
An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancerJ Rubin, D A Decker, D L Ahmann, et al.
Cancer Treatment Reports|January 1, 1980
Phase II evaluation of AMSA in patients with metastatic lung cancerW C Nichols, R T Eagan, S Frytak, et al.
Cancer Clinical Trials|January 1, 1981
A case for preplanned thoracic and prophylactic whole brain radiation therapy in limited small-cell lung cancerR T Eagan, S Frytak, R E Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|July 1, 1980
Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapyR T Eagan, T R Fleming, R E Lee, et al.
Pageof 17